Indoxyl sulfate
|
Basic information |
| Metabolite name | Indoxyl sulfate |
 | HMDB0000682 |
 |
N/A |
 |
10258 |
| Synonyms | 3-indoxyl sulfate; |
| No. of studies | 23 |
|
Basic information |
| Metabolite name | Indoxyl sulfate |
| HMDB0000682 |
|
N/A |
|
10258 |
| Synonyms | 3-indoxyl sulfate; |
| No. of studies | 23 |
|
Relationship between Indoxyl sulfate and depression (count: 23) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Down |
| Study M095 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M095 | Type2 | CUMS + XCHT group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Down |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M1041 | Type2 | pilocarpine + mitochondrial transplantation group vs. pilocarpine group | Hippocampus | C57BL/6J mouse | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1099 | Type3 | fluoxetine group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Urine | Human | Unknown |
| Study M582 | Type1 | CUMS group vs. control group | Serum | C57BL/6N mouse | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Up |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M757 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |